Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer.

Nabholtz, J.-M.; Gelmon, Karen A.; Bontenbal, M.; Spielmann, M.; Catimel, G.; Conte, Pierfranco; Klaassen, U.; Namer, M.; Bonneterre, Jacques; Fumoleau, P.; Winograd, B.

doi:10.1200/jco.1996.14.6.1858

Cited by 353 publications

(152 citation statements)

References 10 publications

Supporting

Mentioning

144

Contrasting

Order By: Relevance

“…ANC values should be interpreted in the context of this heavily pretreated population. This can be contrasted with the data of Nabholtz et al, 23 who reported Grade 3/4 neutropenia in 34% of first cycles using 175 mg/m 2 paclitaxel in patients with only 1 previous chemotherapy regimen. Given the finding that 9 of the 10 patients who had their dose escalated from 8 to 10 mg/m 2 per day in the second cycle tolerated this dose well, we recommend for Phase II studies that the dose of ixabepilone administered daily for 3 days every 21 days should be 8 -10 mg/m 2 per day on 3 consecutive days, starting with a dose of 8 mg/m 2 per day.…”

Section: Discussioncontrasting

confidence: 55%

A Phase I clinical trial of ixabepilone (BMS‐247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days

Zhuang

Agrawal

Edgerly

et al. 2005

Cancer

View full text Add to dashboard Cite

BACKGROUNDThe epothilones are a novel class of microtubule‐stabilizing agents. Ixabepilone (BMS‐247550; NSC 710428) is a semisynthetic analog of the natural product epothilone B. The authors conducted a Phase I study by administering ixabepilone to patients as a 1‐hour intravenous infusion daily for 3 consecutive days every 21 days.METHODSTwenty‐six patients were enrolled and received ixabepilone at a starting dose of 8 or 10 mg/m2 per day for 3 consecutive days.RESULTSOne hundred and nineteen cycles were administered to 26 patients. The maximum‐tolerated dose was 8 mg/m2 per day of ixabepilone administered as a 1‐hour intravenous infusion daily for 3 consecutive days every 21 days. The dose‐limiting toxicity (DLT) was neutropenia. Other nonhematologic Grade 3 toxicities included fatigue (3 cycles), hyponatremia (1 cycle), anorexia (1 cycle), ileus (1 cycle), stomatitis (1 cycle), and emesis (1 cycle). Prolonged disease stabilization was observed in patients with mesothelioma, ovarian carcinoma, and renal cell carcinoma.CONCLUSIONSThe recommended Phase II dose of ixabepilone on the daily schedule for 3 days was 8–10 mg/m2 per day. Neutropenia was the DLT. Peripheral neuropathy was mild, even after multiple cycles of therapy, and was not dose limiting. Cancer 2005. Published 2005 by the American Cancer Society.

show abstract

Section: Discussioncontrasting

confidence: 55%

A Phase I clinical trial of ixabepilone (BMS‐247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days

Zhuang

Agrawal

Edgerly

et al. 2005

Cancer

View full text Add to dashboard Cite

show abstract

“…[1][2][3][4][5][6][7] The effectiveness of paclitaxel in metastatic anthracycline-resistant breast cancer led to several large adjuvant clinical trials. The first of these to be reported, US Intergroup trial INT 0148 (CALGB 9344), demonstrated an improvement in diseasefree and overall survival from the addition of four cycles of paclitaxel to four cycles of cyclophosphamide and doxorubicin.…”

Section: Introductionmentioning

confidence: 99%

Estrogen Receptor Expression and Sensitivity to Paclitaxel in Breast Cancer

Dougherty¹,

Schumaker²,

Jordan³

et al. 2004

Cancer Biology & Therapy

View full text Add to dashboard Cite

ACKNOWLEDGEMENTS Research Paper Estrogen Receptor Expression and Sensitivity to Paclitaxel in Breast Cancer ABSTRACTA retrospective analysis of CALGB trial 9344 suggested paclitaxel administration following cyclophosphamide and doxorubicin adjuvant chemotherapy is most beneficial for patients with ERα negative (ERα-) breast cancer. Since the cytotoxic effects of paclitaxel are cell cycle dependent, we postulated that the relationship between ERα and the effectiveness of adjuvant paclitaxel reflects the observation that ERα positive (ERα+) breast cancers proliferate more slowly than ERα-breast cancers. Three in vitro models (MCF-7, T47D and ZR-75) were examined to compare growth rates and paclitaxelinduced apoptosis in ERα+ and ERα-clones of the same, originally ERα+ cell line. For the T47D and ZR-75 cell lines, loss of ERα was associated with a decrease in doubling time and an increase in paclitaxel sensitivity. However, when cell culture conditions were altered to achieve equivalent cell proliferation rates, no difference in paclitaxel sensitivity was observed. Similarly, an ERα-clone of MCF-7 cells that did not exhibit an enhanced growth rate compared to its ERα+ counterpart also did not show increased paclitaxel sensitivity. The combined apoptotic effects of tamoxifen and paclitaxel on MCF-7 cells were not synergistic or even clearly additive. In these in vitro models, the effectiveness of paclitaxel correlated more closely with growth rate than ERα expression. These data suggest that measurements of tumor proliferation may provide more accurate predictive markers for the benefits of adjuvant paclitaxel than ERα analysis.

show abstract

“…However, many patients receiving prolonged oncological treatment suffer from complications caused by adverse effects of these treatments. These patients may experience a poor quality of life and will often still relapse post-treatment (Goldfarb and Ben-Eliyahu, 2006;Nabholtz et al, 1996;Valero et al, 1995). The main reason current treatment options fail is thought to be due to cancer stem cells, which cannot be eradicated by traditional treatment modalities.…”

Section: Cancersmentioning

confidence: 99%

Stem cell technology and engineering for cancer treatment

Truong

Pham

2015

Biomed Res Ther

View full text Add to dashboard Cite

Abstract-Stem cells are not only widely used for regenerative medicine, but are also considered as a useful tool for cancer treatment. For a long time, stem cells have been utilized to renew the immune system for radiation or chemotherapy treated patients. Recently, stem cells are being engineered to carry therapeutic reagents to target tumor sites. Cancer vaccines based on the knowledge of cancer stem cells have been studied and applied for cancer treatment. Induced pluripotent stem cells have been used to create active T cells to support cancer immunotherapy. Those are due to the unique characteristics of stem cells, such as immunological tolerance, migration, and tissue reparation. This review discusses stem cell applications in transplantation, stem cell-based carriers, induced-pluripotent stem cells, cancer stem cells, and potential of stem cells engineering to revolutionize cancer treatment.

show abstract

Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer.

Cited by 353 publications

References 10 publications

A Phase I clinical trial of ixabepilone (BMS‐247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days

A Phase I clinical trial of ixabepilone (BMS‐247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days

Estrogen Receptor Expression and Sensitivity to Paclitaxel in Breast Cancer

Stem cell technology and engineering for cancer treatment

Contact Info

Product

Resources

About